Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

An enzyme implicated in osteoporosis, arthritis, atherosclerosis and cancer metastasis -- cathepsin K -- eluded reliable detection in laboratory experiments in the past. Now, a research team at the Georgia Institute of Technology has developed an assay that reliably detects and quantifies mature cathepsin K using a technique called gelatin zymography.

2 Jun 2010

Genes influence AIAA side effect in breast cancer survivors

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

2 Jun 2010

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.

2 Jun 2010

Medicare patients may face accessibility crisis to medical care

According to an article in the June issue of the Journal of Bone and Joint Surgery (JBJS), Medicare patients - many who suffer from disabling arthritis of the hip and knee, among other age-related ailments - may end up facing an accessibility crisis to medical care.

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

FDA approves Prolia for postmenopausal women with osteoporosis

The U.S. Food and Drug Administration approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

2 Jun 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.

1 Jun 2010

Targeted Genetics reports net income of $1.8M for fourth-quarter 2009 compared to net loss of $10.8M in 2008

Targeted Genetics Corporation today announced its financial results for the fourth quarter and full year ended December 31, 2009.

1 Jun 2010

BPC mobilizes to ensure patient interests are put first in new BC PharmaCare drug review process

On the verge of a BC Government announcement on a new policy on generic medication pricing and a Long Term Pharmacy Agreement, the Better Pharmacare Coalition (BPC) is mobilizing its two million members to ensure Government keeps its promise that patient interests and input are reflected in the new BC PharmaCare drug review process.

31 May 2010

Canadian hockey legend joins Toronto Walk to Fight Arthritis

This Sunday, May 30, the Arthritis Society brings the Walk to Fight Arthritis, presented by the makers of TYLENOL(R), to communities across Canada, including Toronto, to help raise funds and awareness for the leading cause of disability in Canada.

29 May 2010

Congress needs to replace current outdated Medicare payment system

The Alliance of Specialty Medicine, representing over 100,000 specialty physicians nationwide, released the following statement on Congress's unwillingness to improve and permanently fix the Medicare reimbursement system:

29 May 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

Dosage of statin drugs given to patients with heart disease should be monitored: Study

The type and dosage of statin drugs given to patients to treat heart disease should be proactively monitored as they can have unintended adverse effects, concludes a new study published on bmj.com.

27 May 2010

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

The incidence of rheumatoid arthritis (RA) in women has risen during the period of 1995 to 2007, according to a newly published study by researchers from the Mayo Clinic. This rise in RA follows a 4-decade period of decline and study authors speculate environmental factors such as cigarette smoking, vitamin D deficiency, and lower dose synthetic estrogens in oral contraceptives may be the source of the increase.

27 May 2010

Drug and dosage influence risk of GI bleeding

A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.

27 May 2010

Logical Therapeutics closes $16.9 million Series C equity financing round

Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing. The round was led by existing investor SV Life Sciences, and included Burrill & Company, Novo A/S and Novitas Capital.

27 May 2010

FDA accepts Horizon Pharma's DUEXA NDA for review

Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.

27 May 2010

VisEn Medical announces launch of two new imaging agents at EMIM 2010

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response. The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.

26 May 2010

Study finds disagreement between RA patients and doctors on assessment of disease severity

A novel study by researchers at the University of California, San Francisco found that nearly one-third of Rheumatoid Arthritis (RA) patients differed from their physicians in assessment of their disease severity. The disagreement between patient and doctor evaluation of RA activity was most prevalent in patients with depressive symptoms, and those who had poor overall function.

26 May 2010

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

26 May 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

Genes influence AIAA side effect in breast cancer survivors

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Medicare patients may face accessibility crisis to medical care

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

FDA approves Prolia for postmenopausal women with osteoporosis

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

Targeted Genetics reports net income of $1.8M for fourth-quarter 2009 compared to net loss of $10.8M in 2008

BPC mobilizes to ensure patient interests are put first in new BC PharmaCare drug review process

Canadian hockey legend joins Toronto Walk to Fight Arthritis

Congress needs to replace current outdated Medicare payment system

Amgen announces European approval of Prolia

Dosage of statin drugs given to patients with heart disease should be monitored: Study

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

Drug and dosage influence risk of GI bleeding

Logical Therapeutics closes $16.9 million Series C equity financing round

FDA accepts Horizon Pharma's DUEXA NDA for review

VisEn Medical announces launch of two new imaging agents at EMIM 2010

Study finds disagreement between RA patients and doctors on assessment of disease severity

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in